NCT03114865 A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03109093 Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE2
NCT03072771 Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Status COMPLETED Phase PHASE1
NCT03023878 Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma Status COMPLETED Phase PHASE2
NCT02997761 Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE2
NCT02961881 A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE1
NCT02910063 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL Status COMPLETED Phase PHASE2/PHASE3
NCT02879695 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02877303 Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE2
NCT02811679 A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma Status TERMINATED Phase PHASE2
NCT02807883 Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE2
NCT02790515 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02744768 D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Status UNKNOWN Phase PHASE2
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1
NCT02458014 Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Status COMPLETED Phase PHASE2
NCT02412306 Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT02393859 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Status COMPLETED Phase PHASE3
NCT02187354 Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL Status NO_LONGER_AVAILABLE Phase N/A
NCT02143414 Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02101853 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE3